Overall, regarding the potential cytotoxicity of DT389 and the overexpression of IL-3 on a wide range of cancerous cells, the efficacy of tagraxofusp has been evaluated in numerous clinical trials against hematologic neoplasms such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), BPDCN, and multiple myeloma (MM) (61). The gene discussed is IL3; the disease is acute myeloid leukemia.